{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Definition of Key Study Terms', 'Terms', 'Definition of terms', 'Baseline', 'Assessments of subjects as they enter a trial before they receive any', 'treatment.', 'Endpoint', 'Variable that pertains to the efficacy or safety evaluations of a trial.', 'Enroll', 'To register or enter a subject into a clinical trial. NOTE: Once a subject has', 'received the study drug or placebo, the clinical trial protocol applies to the', 'subject.', 'Investigational', 'Period of time where major interests of protocol objectives are observed, and', 'period', 'where the test drug or comparative drug (sometimes without randomization)', 'is usually given to a subject, and continues until the last assessment after', 'completing administration of the test drug or comparative drug.', 'Randomization', 'The process of assigning trial subjects to treatment or control groups using', 'an element of chance to determine assignments in order to reduce bias.', 'Screening', 'A process of active consideration of potential subjects for enrollment in a', 'trial.', 'Screen failure', 'Potential subject who did not meet 1 or more criteria required for', 'participation in a trial.', 'Screening period', 'Period of time before entering the investigational period, usually from the', 'time when a subject signs the consent until just before the test drug or', 'comparative drug (sometimes without randomization) is given to a subject.', 'Study period', 'Period of time from the first site initiation date to the last site completing the', 'study.', 'Variable', 'Any entity that varies; any attribute, phenomenon or event that can have', 'different qualitative or quantitative values.', '14 Sep 2020', 'Astellas', 'Page 16 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'IV.', 'SYNOPSIS', 'Date and Version # of Protocol Synopsis:', '14 Sep 2020, Version 4.0', 'Study Sponsor:', 'Protocol Number:', 'Astellas Pharma Global Development Inc. (APGD)', '7465-CL-0301', 'Study Collaborator:', 'Seattle Genetics, Inc.', 'Name of Study Drug:', 'Phase of Development:', 'Enfortumab Vedotin (ASG-22CE)', 'Phase 3', 'Title of Study:', 'An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin VS Chemotherapy in', 'Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)', 'Planned Study Period:', '2Q2018 to 2Q2021. The planned study enrollment is approximately 24 months from first subject', 'enrolled with an additional 12 months anticipated for overall survival (OS) follow-up after the last', 'subject enrolled. The total study duration will be approximately 36 months.', 'Study Objective(s):', 'Primary', 'To compare the os of subjects with locally advanced or metastatic urothelial cancer treated', 'with enfortumab vedotin (EV) to the OS of subjects treated with chemotherapy', 'Secondary', 'To compare progression-free survival on study therapy (PFS1) per Response Evaluation', 'Criteria in Solid Tumors (RECIST) V1.1 of subjects treated with EV to subjects treated with', 'chemotherapy', 'To compare the overall response rate (ORR) per RECIST V1.1 of EV to chemotherapy', 'To evaluate the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy', 'To compare the disease control rate (DCR) per RECIST V1.1 of EV to chemotherapy', 'To assess the safety and tolerability of EV', 'To assess quality of life (QOL) and Patient Reported Outcomes (PRO) parameters', 'Exploratory', 'Exploratory genomic and/or other biomarkers in tumor tissue and in peripheral blood that may', 'correlate with treatment outcome, including Nectin-4 expression', 'To assess the pharmacokinetics of EV (total antibody [TAb], antibody-drug conjugate [ADC]', 'and monomethyl auristatin E [MMAE])', 'To assess the incidence of antitherapeutic antibodies (ATA)', 'To evaluate PFS as assessed by RECIST V1.1 by investigator review in the next line of', 'therapy (PFS2) in subjects treated with EV compared to chemotherapy', 'Healthcare resources utilization (HRU)', 'Planned Total Number of Study Centers and Locations:', 'Approximately 185 study centers in North America, Europe, Asia Pacific and Latin America', 'Study Population:', 'Subjects with locally advanced or metastatic urothelial cancer previously treated with platinum-', 'based chemotherapy and an immune checkpoint inhibitor (CPI)', '14 Sep 2020', 'Astellas', 'Page 17 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}